KH631
Phase 2Small molecule
KH631 is one of 35 small molecule programs targeting Age-Related Macular Degeneration. It is currently in Phase 2.
1
Indications
2
Total Trials
2
Active Trials
34
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
43 competitors in Age-Related Macular Degeneration
#DrugCompanyPhaseTrials
1Eylea
RegeneronApproved
Zometa
PfizerApproved
Bayer Aspirin
BayerApproved
Plavix
SanofiApproved
Tecfidera
BiogenApproved
Visudyne
BBausch Health Americas, Inc.
Approved
Bendopa
MMerz North America, Inc.
Approved
Lodosyn
LLaTonya J. Hickson
Approved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for KH631. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details